Wells Fargo & Company Mi Nk Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 10,860 shares of INKT stock, worth $7,927. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,860
Previous 11,017
1.43%
Holding current value
$7,927
Previous $10,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
912KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$170,9520.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$121,6660.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$93,3230.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$70,3330.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$63,6530.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $24.7M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...